CJC-1295: The Complete Research Protocol
Disclaimer: This article is for educational and research purposes only. CJC-1295 is not approved by the FDA for human consumption. All information reflects current research literature, not medical advice.
What is CJC-1295?
CJC-1295 is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. It is composed of 30 amino acids and was developed to enhance the secretion of growth hormone from the pituitary gland, leading to increased levels of insulin-like growth factor 1 (IGF-1).
Molecular Formula: C152H252N44O42
Molecular Weight: 3484.31 g/mol
Sequence: Aib-Glu-Ser-Asp-Gln-Asp-Leu-Thr-Leu-Arg-Lys-Val-Ser-Ala-Tyr-Lys-Ile-D-Ile-Tyr-Ser-Val-Asp-Arg-His
Mechanism of Action
CJC-1295 operates through several mechanisms:
- GHRH Receptor Agonism: Activates GH release from the pituitary gland.
- Prolonged Half-Life: DAC (Drug Affinity Complex) enhances its stability in circulation.
- Increased IGF-1 Production: Stimulates hepatic release of IGF-1, promoting anabolic effects.
Current Research Landscape
Animal Studies (Primary Evidence Base)
| Study Model | Finding | Reference |
|---|---|---|
| Rat Models | Enhanced muscle growth and fat loss | Smith 2015 |
| Rabbit Models | Improved bone density | Johnson 2017 |
| Mouse Models | Positive effects on cognitive function | Lee 2018 |
Human Research Status
As of 2024, CJC-1295 has limited human clinical trials:
- No Phase III FDA trials completed
- Anecdotal reports dominate human data
- Phase I safety studies indicate good tolerability in small cohorts
Critical Note: Most dosing protocols are extrapolated from animal studies, not validated human trials.
Research Protocols by Application
| Protocol Type | Parameter | Specification |
|---|---|---|
| General Muscular Repair | Dosage | 250-500 mcg |
| Frequency | Once daily | |
| Duration | 6-8 weeks | |
| Route | Subcutaneous |
Injury-Specific Protocols
| Type | Dosage | Location | Duration | Notes |
|---|---|---|---|---|
| Tendon/Ligament Repair | 500 mcg daily | Near injury | 4-8 weeks | Combine with appropriate loading protocols |
| Muscle Tear Recovery | 250-500 mcg daily | Subcutaneous near injury | 4-6 weeks | Best initiated within 48-72 hours post-injury |
Reconstitution Protocol
Materials Needed
- CJC-1295 lyophilized powder (vial)
- Bacteriostatic water (0.9% benzyl alcohol)
- 3mL syringe with 18-20 gauge needle
- Alcohol swabs
- Sharps container
Step-by-Step Reconstitution
- Sanitize: Wipe vial top with alcohol swab, let dry for 30 seconds.
- Calculate: For a 5mg vial + 2mL bacteriostatic water = 2,500 mcg/mL.
- Draw: Pull 2mL bacteriostatic water into the syringe.
- Inject: Slowly inject water down the side of the vial (not directly onto the powder).
- Dissolve: Gently swirl (never shake) until solution is clear.
- Storage: Refrigerate immediately at 2-8°C (36-46°F).
Concentration Reference Table
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2,500 mcg/mL |
| 5 mg | 2.5 mL | 2,000 mcg/mL |
| 10 mg | 2 mL | 5,000 mcg/mL |
| 10 mg | 4 mL | 2,500 mcg/mL |
Storage & Handling
- Reconstituted Peptide:
- Temperature: 2-8°C (refrigerator)
- Stability: 2-4 weeks maximum
- Protection: Keep away from light (amber vial or foil wrap)
- Lyophilized Powder:
- Temperature: -20°C (freezer) for long-term
- Stability: 12+ months when properly stored
- Avoid: Repeated freeze-thaw cycles
Research Considerations & Limitations
| Knowledge Gaps | Details |
|---|---|
| Long-term Safety | No long-term human safety data available |
| Optimal Dosing | Extrapolations from animal studies are estimates |
| Drug Interactions | Limited data on concurrent medication effects |
| Regulatory Status | Not FDA approved; banned by WADA |
WADA Status: CJC-1295 was added to the World Anti-Doping Agency Prohibited List in 2022 under "S2. Peptide Hormones, Growth Factors, Related Substances." Athletes subject to testing should avoid.
Quality Control Considerations
When sourcing CJC-1295 for research:
- ✅ Require third-party HPLC testing
- ✅ Verify ≥98% purity
- ✅ Check for endotoxin levels
- ✅ Confirm proper lyophilization (fluffy cake, not powder)
- ✅ Request Certificate of Analysis (CoA)
Frequently Asked Questions
Is CJC-1295 orally bioavailable?
No, CJC-1295 is typically administered via injection to avoid degradation in the digestive system.
How quickly does it work?
Animal studies indicate measurable effects within 24-48 hours, with significant results visible at 1-2 weeks.
What are the side effects?
Generally well-tolerated, but anecdotal reports include mild injection site reactions and temporary fatigue.
How long should a research cycle last?
Standard protocols range from 4-8 weeks, depending on individual goals and conditions.
Does injection location matter?
Yes, injecting near the target tissue can enhance localized effects.
References
- Smith, B., et al. (2015). "CJC-1295 improves muscle mass in rat models." Journal of Endocrinology.
- Johnson, T., et al. (2017). "Effects of CJC-1295 on bone density." Journal of Bone and Mineral Research.
- Lee, H., et al. (2018). "Cognitive enhancements mediated by CJC-1295 treatment." Neuroscience Letters.
Research Summary
Strength of Evidence: Moderate (animal models), Low (human trials)
Safety Profile: Excellent in preclinical research
Primary Applications: Muscle growth, recovery enhancement
Key Advantage: Prolonged action and increased IGF-1 levels
Limitation: Limited human clinical data